Skip to Main Content

Happy New Year! Here is STAT’s biotech scorecard, our regular ledger of stock-moving biotech events, for the first quarter:

Abbvie is developing a cocktail of drugs to treat people with cystic fibrosis, which if proven effective and safe — and eventually approved — might grab a meaningful slice of Vertex Pharma’s $7 billion-plus cystic fibrosis treatment franchise. The probability that this scenario plays out in Abbvie’s favor — or doesn’t — will become clearer once readouts from two mid-stage clinical trials are announced early in the quarter.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


Create a display name to comment

This name will appear with your comment